DERMABOND™ PRINEO™ Skin Closure System
The DERMABOND™ PRINEO™ Skin Closure System offers a powerful, non-invasive alternative to traditional skin sutures and staples. It combines the strength, flexibility, and microbial protection of DERMABOND ADVANCED™ Topical Skin Adhesive with a secure, latex-free, self-adhering mesh to facilitate optimal skin closure and healing.1-7A In a clinical study, the DERMABOND™ PRINEO™ System was associated with a better cosmetic outcome than conventional suturing in skin closure. 8B
.png?width=3840&quality=90&format=webp)
.png?width=3840&quality=90&format=webp)
.png?width=3840&quality=90&format=webp)
.png?width=3840&quality=90&format=webp)
About this device
DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical adhesive paired with a self-adhering mesh. It is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure,4 forming a flexible microbial barrier.5,13,I,J It remains intact for 7–14 days before naturally falling off.4
Specialties
Orthopaedic, OBGYN, Breast, Cardiovascular, Spine
Procedures
Total Knee Arthroplasty, Total Hip Arthroplasty, Abdominoplasty, Breast, Reconstruction, CABG, Valve Replacement, Revisions
Economic benefits
In a retrospective study comparing TJA patients with conventional closure to those who had multilayer watertight closure with STRATAFIX™ Knotless Tissue Control Devices and DERMABOND™ PRINEO™ Skin Closure System, statistically significant advantages were shown for multilayer watertight closure patients including9C:
- Shorter LOS (0.5 days)
- No reoperations within 90 days
- Higher percent of patients discharged to home
- Extended time to readmission
Proven cost savings
In a retrospective cohort study comparing DERMABOND™ PRINEO™ Skin Closure System vs. skin sutures with waterproof closure following sternotomy for cardiac surgery, DERMABOND™ PRINEO™ was associated with10D:
- 1.4 days shorter length of stay
- $10,000 lower total hospital costs
Features & benefits
Stronger closure
DERMABOND™ PRINEO™ is ~33% stronger than skin staples11EF and ~40% stronger than subcuticular 4-0 suture.11,12G
Reduced infection risk
DERMABOND™ PRINEO™ protects incisions with a watertight, microbial barrier. It provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms responsible for SSIs.5,13HI
.png?width=3840&quality=90&format=webp)
Improved cosmesis
While sutures and staples penetrate the skin and place tension on the wounded tissue, DERMABOND™ PRINEO™ redistributes tension across the surrounding healthy skin in a uniform way, which results in improved cosmetic results compared to conventional suturing.8B
Learn how to use this device
Supporting documentation
Related products
DERMABOND ADVANCED™ Topical Skin Adhesive
DERMABOND ADVANCED™ Topical Skin Adhesive holds wound edges together following surgical incisions and lacerations.1 It delivers a microbial barrier with 99% effectiveness for 72 hours in vitro, guarding against organisms commonly responsible for surgical site infections (SSIs).2A Patients also benefit from significantly improved comfort and satisfaction when compared to sutured closures.3,4B
References
A. As demonstrated in vitro.
B. Measured by the Hollander Cosmesis Scale at 2 weeks after surgery and the Vancouver Scar Scale 6 and 12 months after surgery in a prospective, randomized controlled trial (N=60).
C. Total Joint Arthroplasty data extracted from Electronic Medical Records at Valley Medical Center (VMC), based on unadjusted outcomes, University of Washington (p=0.0031), n=2107, 01/2014 – 03/2019
D. Based on a retrospective study of 10,676 patients undergoing cardiac surgery requiring sternotomy in Premier Healthcare Database® (10/2015 – 06/2020).
E. Study performed ex vivo.
F. Based on average max load at or prior to 3+1mm gap (N). Mean (N) for DERMABOND™ PRINEO™ Skin Closure System (22cm) was 166.53 vs 112.40 for skin staples.
G. Study performed ex vivo with 22 cm system.
H. Challenge organisms included Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium.
I. Clinical Significance Unknown.
J. As seen in vitro at 72 hours.
- Keplinger S. Protocol investigation of the comparison of PRINEO with conventional wound closure techniques. 07PD048. May 2007. Ethicon, Inc.
- Thomson CM. Multi‐centre study to show equivalence of DERMABOND PROTAPE to INTRADERMAL SUTURES for skin closure of full thickness surgical incisions associated with breast procedures. Protocol 07CS003. Final Report. July 9, 2010. Ethicon, Inc.
- Lombard J. Multi‐ centre study to show equivalence of DERMABOND PROTAPE to INTRADERMAL SUTURES for skin closure of full thickness surgical incisions. Protocol 06CS005. Final Report. June 10, 2010.
- DERMABOND™ PRINEO™ Skin Closure System Instructions for Use. Ethicon, Inc.
- Shapiro AJ, Dinsmore RC, North JH, Tensile strength of wound closure with cyanoacrylate glue. Am Surg. 2001;67:1113-1115.
- Kannon GA, Garrett AB. Moist wound healing with occlusive dressings. Dermatol Surg. 1995;21:583-590.
- Bhende S. In‐vitro study to evaluate the ability of DERMABOND™ PRINEO™ Skin Closure System to kill bacteria on contact. June 22, 2012. Ethicon, Inc.
- Parvizi D, Friedl H, Schintler MV, et al. Use of 2‐octyl cyanoacrylate together with a self‐adhering mesh (Dermabond Prineo) for skin closure following abdominoplasty: an open, prospective, controlled, randomized, clinical study. Aesthetic Plast Surg. 2013;37(3):529‐ 537.
- Flener, JL., Chen, BP., Ernst FR., Libolt, A. & Barrett, WP. (2022) Advanced Multi‐Layer, Watertight Closure in Total Joint Replacement: A Retrospective Study. Value in Health, Volume 25, Issue 12S, CO75 (December 2022).
- Ethicon: Clinical and Economic Outcomes after sternotomy for cardiac surgery with skin closure through 2‐ octyl cyanoacrylate plus polymer mesh tape versus absorbable sutures plus waterproof wound dressings, Q2 2021.
- Kumar A. Study to compare the tissue holding strengths of DERMABOND™ PRINEO™ 22 cm Skin Closure System (DP22) to conventional wound closure techniques. AST‐2014‐0246. September 25, 2014. Ethicon, Inc.
- Kumar A. Completion Report: Study to compare the tissue holding strength of PRINEO™ skin closure system with conventional wound closure techniques. AST 2012‐0290. October 11, 2012. Ethicon, Inc.
- Su W. Study Report for in vitro evaluation of microbial barrier properties of Dermabond™ Protape. 06TR071. December 4, 2006. Ethicon, Inc.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
The third-party trademarks used herein are trademarks of their respective owners.
US_SRG_WOUN_117938.1